These inhibitors work by blocking the binding of PD-1 to its ligand PD-L1, restoring the anti-tumor activity of NK cells and T cells, and increasing their cytotoxicity and secretion of immune factors such as IFN-γ and TNF-α. This evidence concerns the gene IFNG and neoplasm.